Основная статистика
| LEI | 549300BYFRN3JS60MY33 |
| CIK | 946644 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AIM ImmunoTech Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified |
|
| August 14, 2025 |
Agreement between Company and Messrs. Equels and Rodino dated April 1, 2025.* Exhibit 10.1 AGREEMENT THIS AGREEMENT (the “Agreement”) is made as of April 1, 2025, by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), Thomas K. Equels (the “Equels”) and Peter W. Rodino III (“Rodino” and with Equels, the “Officers”). RECITALS WHEREAS, the Company desires to restrict the Officers’ ability to sell the shares of Company common stock, $0.001 par value (the “ |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorpo |
|
| July 31, 2025 |
the Placement Agency Agreement with Maxim Group LLC Exhibit 1.01 PLACEMENT AGENCY AGREEMENT July 28, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and AIM ImmunoTech Inc., a Delaware corporation (the “Company”), pursuant to which the Placement Agent shall serve as the placement agent for the |
|
| July 31, 2025 |
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering Exhibit 99.1 AIM ImmunoTech Announces Closing of $8.0 Million Public Offering OCALA, Fla., July 31, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common sto |
|
| July 31, 2025 |
the form of Pre-Funded Warrant Exhibit 4.27 PREFUNDED PURCHASE WARRANT AIM IMMUNOTECH INC. Warrant Shares: Initial Exercise Date: July 30, 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, . or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| July 31, 2025 |
Exhibit 10.63 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 28, 2025, between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| July 31, 2025 |
the Warrant Agency Agreement with the warrant agent Exhibit 4.28 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of July 30, 2025 (“Agreement”), by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”). W I T N E S S E T H WHEREAS, pursuant to a registered offering by the Company of units comprised of shares of the Company’s Common Stock (as defined below) (or pref |
|
| July 31, 2025 |
the form of Class E/F Warrants Exhibit 4.26 CLASS [E/F] COMMON STOCK PURCHASE WARRANT AIM IMMUNOTECH INC. Warrant Shares: Initial Exercise Date: July 30, 2025 THIS CLASS [E/F] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| July 30, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-284443 AIM ImmunoTech Inc. Up to 2,000,000 Units, each consisting of One Share of Common Stock or One Pre-Funded Warrant to purchase One Share of Common Stock, One Class E Warrant to purchase One Share of Common Stock and One Class F Warrant to purchase One Share of Common Stock Up to 2,000,000 Shares of Common Stock Underlying the Pre-Funded W |
|
| July 28, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorpo |
|
| July 28, 2025 |
Exhibit 99.1 AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer Mid-year report of combination therapy demonstrates promising signs of both no significant toxicity and superior PFS and OS OCALA, Fla., July 28, 2025/ AIM ImmunoTech Inc. |
|
| July 28, 2025 |
DURIPANC, Mid-Year Interim Clinical Progress Update Exhibit 99.2 DURIPANC, Mid-Year Interim Clinical Progress Update A Phase I/II Open Label Study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in Pancreatic Cancer Patients with Stable Disease Post-FOLFIRINOX Study Title: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy |
|
| July 24, 2025 |
July 24, 2025 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| July 24, 2025 |
July 24, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: AIM ImmunoTech Inc. Registration Statement on Form S-1, as amended File No. 333-284443 Ladies and Gentlemen: As the placement agent of the proposed offering of AIM ImmunoTech Inc. (the “Company”), we hereby join the Company’s request for acceleration of |
|
| July 22, 2025 |
As filed with the Securities and Exchange Commission on July 22, 2025 Registration No. |
|
| July 15, 2025 |
Opinion of Silverman Shin & Schneider PLLC* Exhibit 5.1(ii) SILVERMAN SHIN & SCHNEIDER PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212.779.8600 Facsimile: 212.779.8858 July 15, 2025 Board of Directors AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala FL 34473 Ladies and Gentlemen: This opinion letter replaces the prior opinion letter dated February 3, 2025 and adjusts numbers to take into account the reverse stock split |
|
| July 15, 2025 |
Exhibit 4.27 PREFUNDED PURCHASE WARRANT AIM IMMUNOTECH INC. Warrant Shares: [] Initial Exercise Date: [], 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini |
|
| July 15, 2025 |
As filed with the Securities and Exchange Commission on July 15, 2025 As filed with the Securities and Exchange Commission on July 15, 2025 Registration No. |
|
| July 15, 2025 |
Opinion of Silverman Shin & Schneider PLLC*** Exhibit 5.1(i) SILVERMAN SHIN & SCHNEIDER PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212.779.8600 Facsimile: 212.779.8858 February 3, 2025 Board of Directors AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala FL 34473 Ladies and Gentlemen: We have acted as counsel to AIM ImmunoTech Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Fo |
|
| July 15, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) AIM ImmunoTech Inc. |
|
| July 15, 2025 |
As filed with the Securities and Exchange Commission on July 15, 2025 Registration No. |
|
| July 15, 2025 |
SILVERMAN SHIN & BYRNE PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212. |
|
| July 15, 2025 |
Form of Warrant Agency Agreement between AIM and Equiniti Trust Company, LLC* Exhibit 4.28 FORM OF WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”). W I T N E S S E T H WHEREAS, pursuant to a registered offering by the Company of units comprised of shares of the Company’s Common Stock (as defined below) (or pre |
|
| July 15, 2025 |
Form of Placement Agent Warrant* Exhibit 4.29 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT AIM ImmunoTech Inc. Warrant Shares: Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| July 15, 2025 |
Exhibit 4.26 CLASS [E/F] COMMON STOCK PURCHASE WARRANT AIM IMMUNOTECH INC. Warrant Shares: [ Initial Exercise Date: [], 2025 THIS CLASS [E/F] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| June 30, 2025 |
June 30, 2025 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| June 27, 2025 |
SILVERMAN SHIN & BYRNE PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212. |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025 As filed with the Securities and Exchange Commission on June 27, 2025 Registration No. |
|
| June 20, 2025 |
Exhibit 99.1 AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance Ocala, FL, June 20, 2025–AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 17, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorpo |
|
| June 12, 2025 |
Exhibit 99.2 AIM ImmunoTech Announces NYSE American Removal of Trading Suspension Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025 OCALA, Fla., June 12, 2025/ AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorpor |
|
| June 12, 2025 |
Exhibit 3.1(i) |
|
| June 12, 2025 |
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split Exhibit 99.1 AIM ImmunoTech Announces 1-for-100 Reverse Stock Split OCALA, Fla., June 11, 2025/ AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company’s ticker symbol on the OTC |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specifie |
|
| May 15, 2025 |
EXHIBIT 10.1 FORBEARANCE AGREEMENT This Forbearance Agreement (this “Agreement”) is entered into as of May 13, 2025 by and between Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and AIM ImmunoTech, Inc., a Delaware corporation (“Borrower”). Capitalized terms used in this Agreement without definition shall have the meanings given to them in the Note (defined below). A. Bor |
|
| May 1, 2025 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorp |
|
| April 7, 2025 |
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal Exhibit 99.1 AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal April 4, 2025–AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorpo |
|
| April 4, 2025 |
Exhibit 1.1 AIM ImmunoTech Inc. Up to $3,000,000 Shares of Common Stock Equity Distribution Agreement April 1, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: AIM ImmunoTech Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as sales agent, shares of common stock, par value $0.001 per share |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of incorpo |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 1, 2025 |
Equity Distribution Agreement, dated April 1, 2025* Exhibit 10.1 AIM ImmunoTech Inc. Up to $3,000,000 Shares of Common Stock Equity Distribution Agreement April 1, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: AIM ImmunoTech Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as sales agent, shares of common stock, par value $0.001 per shar |
|
| April 1, 2025 |
Exhibit 4.8 AIM IMMUNOTECH, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Series |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on April 1, 2025 As filed with the Securities and Exchange Commission on April 1, 2025 Registration No. |
|
| April 1, 2025 |
Calculation of Filing Fee Table* Exhibit 107 Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 AIM ImmunoTech Inc. |
|
| March 27, 2025 |
Exhibit 21.1 Subsidiaries US Subsidiaries: Status BioPro Corp. Dormant BioAegean Corp. Dormant Foreign Subsidiaries: Aim ImmunoTech Europe N.V./S.A. (Belgium) |
|
| March 27, 2025 |
Exhibit 19.1 Insider Trading Policy The Insider Trading Policy of AIM ImmunoTech Inc. (the “Company”) is contained in its Code of Ethics. Section B.1. of the Code of Ethics states: DO NOT ENGAGE IN SPECULATIVE OR INSIDER TRADING Federal law and Company policy prohibits officers, directors, and employees, directly or indirectly through their families or others, from purchasing or selling Company st |
|
| March 27, 2025 |
Exhibit 4.11 Description of Common Stock The following summary description of the common stock of AIM ImmunoTech Inc. (“we”, “our” or “us”) is based on the provisions of our amended and restated certificate of incorporation as amended (“Certificate of Incorporation”), as well as our amended and restated bylaws (“Bylaws”), and the applicable provisions of the Delaware General Corporation Law. This |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-27072 AIM IMMUNOTECH INC. (Exact na |
|
| February 28, 2025 |
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance Exhibit 99.1 AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance OCALA, Fla., February 26, 2025/ AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s Plan to regain compliance with the minimum stockholders’ equity requirements |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 26, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 26, 2025 |
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director Exhibit 99.1 AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director OCALA, Fla., February 26, 2025/ AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| February 26, 2025 |
Exhibit 3.7(ii) RESTATED AND AMENDED BYLAWS Of AIM IMMUNOTECH INC. [f/k/a HEMISPHERX BIOPHARMA, INC.] (February 24, 2025) ARTICLE I. MEETINGS OF STOCKHOLDERS. Section 1.1. Annual Meeting. The annual meeting of stockholders shall be held at such date, time and place, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time. In li |
|
| February 13, 2025 |
February 13, 2025 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We hereby withdraw our request for acceleration of the effective date for our registration statement on Form S-1 (File No. |
|
| February 11, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| February 11, 2025 |
Exhibit 99.1 AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 OCALA, Fla., February 11, 2025/ AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its R |
|
| February 11, 2025 |
Exhibit 99.1 AIM ImmunoTech Releases Virtual Investor “What This Means Segment” Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic |
|
| February 7, 2025 |
As filed with the Securities and Exchange Commission on February 7, 2025 As filed with the Securities and Exchange Commission on February 7, 2025 Registration No. |
|
| February 7, 2025 |
Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampli |
|
| February 7, 2025 |
Form of Placement Agent Warrant*** Exhibit 4.29 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT AIM ImmunoTech Inc. Warrant Shares: Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inco |
|
| February 6, 2025 |
February 6, 2025 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2025 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inco |
|
| February 5, 2025 |
Exhibit 99.1 Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities |
|
| February 3, 2025 |
Form of Warrant Agency Agreement between AIM and Equiniti Trust Company, LLC* Exhibit 4.28 FORM OF WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”). W I T N E S S E T H WHEREAS, pursuant to a registered offering by the Company of units comprised of shares of the Company’s Common Stock (as defined below) (or pre |
|
| February 3, 2025 |
Exhibit 4.27 PREFUNDED PURCHASE WARRANT AIM IMMUNOTECH INC. Warrant Shares: [] Initial Exercise Date: [], 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini |
|
| February 3, 2025 |
Placement Agency Agreement between AIM and Maxim* Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [ ], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and AIM ImmunoTech Inc., a Delaware corporation (the “Company”), pursuant to which the Placement Agent shall serve as the placement agent for the Compa |
|
| February 3, 2025 |
Calculation of Filing Fee Table* Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) AIM ImmunoTech Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Equity Common Stock, p |
|
| February 3, 2025 |
Form of Securities Purchase Agreement between Investor and AIM in this offering* Exhibit 10.118 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2025, between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| February 3, 2025 |
As filed with the Securities and Exchange Commission on February 3, 2025 As filed with the Securities and Exchange Commission on February 3, 2025 Registration No. |
|
| February 3, 2025 |
Exhibit 10.119 LOCK-UP AGREEMENT , 2025 Maxim Group LLC, as placement agent in the Offering (as defined below) Re: AIM ImmunoTech Inc. Offering Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the closing of the offering of registered securities by AIM ImmunoTech Inc. (the “Company”) pursuant to an effective regis |
|
| February 3, 2025 |
Exhibit 4.26 CLASS [E/F] COMMON STOCK PURCHASE WARRANT AIM IMMUNOTECH INC. Warrant Shares: [ Initial Exercise Date: [], 2025 THIS CLASS [E/F] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| January 23, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) AIM ImmunoTech Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Equity Common Stock, p |
|
| January 23, 2025 |
SILVERMAN SHIN & BYRNE PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212. |
|
| January 23, 2025 |
As filed with the Securities and Exchange Commission on January 23, 2025 As filed with the Securities and Exchange Commission on January 23, 2025 Registration No. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| December 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| December 17, 2024 |
EX-99.2 3 d863168dex992.htm EX-99.2 EXHIBIT 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of the Common Stock of the Company and further agree that this Joint Filing |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| December 17, 2024 |
Exhibit 99.1 AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards A Plan for Compliance has been Undertaken OCALA, Fla., December 17, 2024/AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated December 11, 2024, not |
|
| December 17, 2024 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by |
|
| December 17, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A 1 d863168dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner Paul W. Sweeney Wayne Springate c/o Baker & Hostetler |
|
| December 17, 2024 |
EX-99.1 EXHIBIT 1 JOINDER AGREEMENT This JOINDER AGREEMENT (the “Joinder”) is dated as of December 14, 2024 by and among Ted D. Kellner (the “Nominating Stockholder”), as nominating stockholder and a nominee, and Todd Deutsch, Robert L. Chioini and Paul Sweeney (the “Other Nominees,” and together with the Nominating Stockholder, the “Nominees”), and William A. Carter and Wayne Springate (the “Coop |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 4, 2024 |
AIM ImmunoTech Inc. 9,306,072 Shares Common Stock Prospectus Supplement (to Prospectus dated February 4, 2022) 9,306,072 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 27, 2024 |
Press Release dated November 27, 2024. EX-99.1 2 ex99-1.htm Exhibit 99.1 AIM ImmunoTech Announces Cash Conservation Plan Independent Board Members to Receive 100% of Director Compensation in AIM Stock Follows Previously Disclosed Amendments to Executive Employment Agreements to Reduce Cash Component of Compensation for CEO and COO Board and Management are Deeply Aligned with All AIM Shareholders and Remain Committed to Unlocking the Fu |
|
| November 27, 2024 |
Exhibit 1 |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 25, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| November 27, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 25, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (IRS Employer of inc |
|
| November 27, 2024 |
Exhibit 99.1 AIM ImmunoTech Announces Cash Conservation Plan Independent Board Members to Receive 100% of Director Compensation in AIM Stock Follows Previously Disclosed Amendments to Executive Employment Agreements to Reduce Cash Component of Compensation for CEO and COO Board and Management are Deeply Aligned with All AIM Shareholders and Remain Committed to Unlocking the Full Potential of Ampli |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 26, 2024 |
November 26, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 15, 2024 |
Calculation of Filing Fee Table* Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-1 (Form Type) AIM ImmunoTech Inc. |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 15, 2024 |
SILVERMAN SHIN & SCHNEIDER PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212. |
|
| November 15, 2024 |
As filed with the Securities and Exchange Commission on November 15, 2024 As filed with the Securities and Exchange Commission on November 15, 2024 Registration No. |
|
| November 14, 2024 |
Exhibit 3.1(i)(1) |
|
| November 14, 2024 |
Exhibit 10.15 AIM ImmunoTech Inc 604 Main Street Riverton, NJ 08077 September 19, 2024 604 Associates LLC 701 Bank Avenue Riverton, NJ 08077 Attn: Lawrence R Antonucci Re: Lease Renewal Dear Larry, This letter is in response to your email dated September 19, 2024. We are happy to renew the lease on the property at the above address for another one-year (12 month) term as defined in Section 1(b) of |
|
| November 14, 2024 |
AIM / AIM ImmunoTech Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-aim093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 14, 2024 |
Exhibit 4.1 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as spec |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 30, 2024 |
PRELIMINARY COPY SUBJECT TO COMPLETION — DATED OCTOBER 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 30, 2024 |
Patrick Gadson [email protected] Tel +1.212.237.0198 October 30, 2024 VIA EMAIL AND EDGAR Christina Chalk Associate Chief Eddie Kim Special Counsel Office of Mergers and Acquisitions Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3561 Re: AIM IMMUNOTECH INC. PREC14A filed October 15, 2024 File No. 001-27072 Dear Ms. Chalk |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confiden |
|
| October 15, 2024 |
PRELIMINARY COPY SUBJECT TO COMPLETION — DATED OCTOBER 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 1, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 30, 2024, between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| October 1, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT September 30, 2024 Thomas K. Equels, M.S. J.D. Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala, FL 34473 Dear Mr. Equels: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and AIM ImmunoTech Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the excl |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report September 30, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Ident |
|
| October 1, 2024 |
Prospectus Supplement (to Prospectus dated February 4, 2022) 4,653,036 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 1, 2024 |
Exhibit 99.1 AIM ImmunoTech Inc. OCALA, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered direct offering at a purchase price of $0.27 per share. In a concurrent private pla |
|
| October 1, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 30, 2024 |
Up to $3,300,000 Common Stock AIM ImmunoTech Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-262280 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022) Up to $3,300,000 Common Stock AIM ImmunoTech Inc. This prospectus supplement amends and supplements the information in the prospectus, dated February 4, 2022, filed as a part of our registration statement on Form S-3 (File No. 333-262280), or the Base Prospectus, as supplemente |
|
| September 12, 2024 |
EXHIBIT 10.2 AMENDMENT THIS AMENDMENT (the “Amendment”) is made as of September 11, 2024, by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Peter W. Rodino, III (the “Employee”). RECITALS WHEREAS, the Employee entered into an amended and restated employment agreement with the Company dated March 24, 2021 (the Agreement”); WHEREAS, the Employee entered into an amendmen |
|
| September 12, 2024 |
EXHIBIT 10.1 AMENDMENT THIS AMENDMENT (the “Amendment”) is made as of September 11, 2024, by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Thomas K. Equels (the “Employee”). RECITALS WHEREAS, the Employee entered into an amended and restated employment agreement with the Company dated November 10, 2020 (the Agreement”); WHEREAS, the Employee entered into an amendment |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report September 11, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Ident |
|
| September 11, 2024 |
EX-99.2 3 d848546dex992.htm EX-99.2 EXHIBIT 2 JOINDER AGREEMENT This JOINDER AGREEMENT (the “Joinder”) is dated as of September 11, 2024 by and among Ted D. Kellner (the “Nominating Stockholder”), as nominating stockholder and a nominee, and Todd Deutsch and Robert L. Chioini (the “Other Nominees,” and together with the Nominating Stockholder, the “Existing Nominees”), and Paul Sweeney (the “New N |
|
| September 11, 2024 |
Ted D. Kellner 790 North Water Street, Suite 2175 Milwaukee, WI 53202 EX-99.1 2 d848546dex991.htm EX-99.1 EXHIBIT 1 Ted D. Kellner 790 North Water Street, Suite 2175 Milwaukee, WI 53202 September 11, 2024 VIA OVERNIGHT DELIVERY AND EMAIL AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala, Florida 34473 Attn: Secretary [email protected] Re: Supplement to Notice of Stockholder Intent to Nominate Individuals for Election as Directors at the 2024 Annual Meeting of Stoc |
|
| September 11, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A 1 d848546dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner Paul W. Sweeney c/o Baker & Hostetler LLP 127 Public S |
|
| September 11, 2024 |
EX-99.3 4 d848546dex993.htm EX-99.3 EXHIBIT 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of the Common Stock of the Company and further agree that this Joint Filing |
|
| September 3, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A 1 d854691dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 200 |
|
| September 3, 2024 |
EX-99.2 3 d854691dex992.htm EX-99.2 Exhibit 2 Agreement THIS AGREEMENT (the “Agreement”), dated as of September 3, 2024 (the “Effective Date”), is by and among Ted D. Kellner (the “Nominating Stockholder”), as nominating stockholder and a nominee, and Todd Deutsch and Robert L. Chioini (the “Other Nominees”), as additional nominees (each, a “Party” and, collectively, the “Parties”). WHEREAS, each |
|
| September 3, 2024 |
Ted D. Kellner 790 North Water Street, Suite 2175 Milwaukee, WI 53202 EX-99.1 2 d854691dex991.htm EX-99.1 Exhibit 1 Ted D. Kellner 790 North Water Street, Suite 2175 Milwaukee, WI 53202 September 3, 2024 VIA OVERNIGHT DELIVERY AND EMAIL AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala, Florida 34473 Attn: Secretary [email protected] Re: Notice of Stockholder Intent to Nominate Individuals for Election as Directors at the 2024 Annual Meeting of Stockholders of AIM |
|
| August 14, 2024 |
EXHIBIT 10.5 AMENDMENT THIS AMENDMENT (the “Amendment”) is made as of August 12 2024, by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Peter W. Rodino, III (the “Employee”). RECITALS WHEREAS, the Employee entered into an amended and restated employment agreement with the Company dated March 24, 2021 (the Agreement”); WHEREAS, pursuant to Section 14 of the Agreement, |
|
| August 14, 2024 |
EXHIBIT 10.4 AMENDMENT THIS AMENDMENT (the “Amendment") is made as of August 12 2024, by and between AIM ImmunoTech Inc., a Delaware corporation (the “Company"), and Thomas K. Equels (the “Employee”). RECITALS WHEREAS, the Employee entered into an amended and restated employment agreement with the Company dated November 10, 2020 (the Agreement”); WHEREAS, pursuant to Section 14 of the Agreement, t |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified |
|
| August 14, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 2000 Cleveland, Ohio 44114 Attn: |
|
| August 1, 2024 |
Exhibit 3.1(ii) RESTATED AND AMENDED BYLAWS Of AIM IMMUNOTECH INC. [f/k/a HEMISPHERX BIOPHARMA, INC.] (July 31, 2024) ARTICLE I. MEETINGS OF STOCKHOLDERS. Section 1.1. Annual Meeting. The annual meeting of stockholders shall be held at such date, time and place, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time. In lieu o |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report July 31, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identifica |
|
| July 30, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 2000 Cleveland, Ohio 44114 Attn: |
|
| July 25, 2024 |
AIM ImmunoTech Inc. 11,281,916 Shares Common Stock Prospectus Supplement (to Prospectus dated February 4, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 22, 2024 |
July 22, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| July 19, 2024 |
July 19, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| July 15, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 2000 Cleveland, Ohio 44114 Attn: |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report July 12, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identifica |
|
| July 11, 2024 |
Calculation Of Filing Fee Table * Exhibit 107.1 CALCULATION OF FILING FEE TABLE Form S-1 (Form Type) AIM ImmunoTech Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity (3) (4) Common stock, par value $0.001 per share Other 11,281,9 |
|
| July 11, 2024 |
SILVERMAN SHIN & SCHNEIDER PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212. |
|
| July 11, 2024 |
As filed with the Securities and Exchange Commission on July 11, 2024 As filed with the Securities and Exchange Commission on July 11, 2024 Registration No. |
|
| July 1, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) AIM ImmunoTech Inc. |
|
| July 1, 2024 |
As filed with the Securities and Exchange Commission on July 1, 2024 As filed with the Securities and Exchange Commission on July 1, 2024 Registration No. |
|
| June 3, 2024 |
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering Exhibit 99.1 AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering OCALA, Fla., May 31, 2024 – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 |
|
| June 3, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 3, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT May 31, 2024 Thomas K. Equels, M.S. J.D. Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala, FL 34473 Dear Mr. Equels: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and AIM ImmunoTech Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the exclusive |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report May 31, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identificat |
|
| June 3, 2024 |
5,640,958 Shares of Common Stock AIM IMMUNOTECH INC. Prospectus Supplement (to Prospectus dated February 4, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| June 3, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 31, 2024, between AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| May 31, 2024 |
Up to $8,150,000 Common Stock AIM ImmunoTech Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-262280 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022) Up to $8,150,000 Common Stock AIM ImmunoTech Inc. This prospectus supplement amends and supplements the information in the prospectus, dated February 4, 2022, filed as a part of our registration statement on Form S-3 (File No. 333-262280), or the Base Prospectus, as supplemente |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specifie |
|
| May 1, 2024 |
AIM ImmunoTech Inc. 9,975,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-278839 PROSPECTUS AIM ImmunoTech Inc. 9,975,000 Shares of Common Stock This prospectus relates to the offer and resale of up to 9,975,000 shares of our Common Stock, par value $0.001 per share, by Atlas Sciences, LLC, which we refer to in this prospectus as Atlas or the selling stockholder. The shares of Common Stock being offered by the sellin |
|
| April 25, 2024 |
[Put on AIM letterhead] April 25, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: AIM ImmunoTech Inc. |
|
| April 19, 2024 |
EXHIBIT 10.107 ADDENDUM NO. 1 TO LEASE WHEREAS a Shopping Center Lease Agreement was entered into on June 13, 2018, by and between SML FL Holdings LLC as the original Lessor and Hemispherx Biopharma, Inc. now AIM ImmunoTech Inc., as Lessee (hereinafter “Lease”), for that portion of the property located in the County/parish of Marion, State of Florida, more particularly described as: 2117 SW Highwa |
|
| April 19, 2024 |
As filed with the Securities and Exchange Commission on April 19, 2024 As filed with the Securities and Exchange Commission on April 19, 2024 Registration No. |
|
| April 19, 2024 |
EXHIBIT 10.106 AIM ImmunoTech Inc 604 Main Street Riverton, NJ 08077 DATE: October 4, 2023 604 Associates LLC 701 Bank Avenue Riverton, NJ 08077 Attn: Lawrence R Antonucci Re: Lease Renewal Dear Larry, This letter is in response to your email dated September 26, 2023. We accept the $150 increase in base rent and would like to renew the lease on the property at the above address for another one-yea |
|
| April 19, 2024 |
Calculation Of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-1 (Form Type) AIM ImmunoTech Inc. |
|
| April 19, 2024 |
SILVERMAN SHIN & SCHNEIDER PLLC Wall Street Plaza 22nd Floor 88 Pine Street NEW YORK, NY 10005 212. |
|
| April 1, 2024 |
Exhibit 97.1 AIM ImmunoTech Inc. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of AIM ImmunoTech Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore ado |
|
| April 1, 2024 |
Exhibit 4.25 Description of Common Stock The following summary description of the common stock of AIM ImmunoTech Inc. (“we”, “our” or “us”) is based on the provisions of our amended and restated certificate of incorporation as amended (“Certificate of Incorporation”), as well as our amended and restated bylaws (“Bylaws”), and the applicable provisions of the Delaware General Corporation Law. This |
|
| April 1, 2024 |
Exhibit 21.1 Subsidiaries US Subsidiaries: Status BioPro Corp. Dormant BioAegean Corp. Dormant Foreign Subsidiaries: Aim ImmunoTech Europe N.V./S.A. (Belgium) |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-27072 AIM IMMUNOTECH INC. (Exact na |
|
| April 1, 2024 |
Exhibit 10.105 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 28, 2024, is entered into by and between AIM IMMUNOTECH, INC., a Delaware corporation (the “Company”), and ATLAS SCIENCES, LLC, a Utah limited liability company (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shal |
|
| April 1, 2024 |
Exhibit 10.104 EQUITY PURCHASE AGREEMENT This Equity Purchase Agreement is entered into as of March 28, 2024 (this “Agreement”), by and between AIM ImmunoTech, Inc., a Delaware corporation (the “Company”), and Atlas Sciences, LLC, a Utah limited liability company (the “Investor”, and collectively with the Company, the “Parties”). WHEREAS, the Parties desire that, upon the terms and subject to the |
|
| February 20, 2024 |
Exhibit 10.2 |
|
| February 20, 2024 |
Exhibit 10.1 |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report February 16, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identi |
|
| February 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report February 8, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identif |
|
| February 9, 2024 |
Exhibit 99.1 AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., February 8, 2024 / AIM Immun |
|
| January 25, 2024 |
Pancreatic Cancer Early Access Program Supplemental Data Q1 2024 Deck. Exhibit 99.1 |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report January 25, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identif |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report January 10, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identif |
|
| January 10, 2024 |
Exhibit 99.1 AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 3, 2024 |
Kellner Group Press Release, dated January 3, 2024 EX-99.1 2 d874197dex991.htm EX-99.1 Exhibit 1 Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied Court Found that Several AIM Advance Notice Bylaws Are Invalid January 3, 2024: Ted D. Kellner, Todd Deutsch and Robert L. Chioini (collectively, the “Kellner Group”) today issue the following statement in connection with their efforts to bring account |
|
| January 3, 2024 |
Amendment to Group Agreement, dated January 3, 2024 EX-99.2 3 d874197dex992.htm EX-99.2 Exhibit 2 Amendment to Group Agreement THIS AMENDMENT, dated as of January 3, 2024 (the “Amendment”), to that certain AGREEMENT (the “Agreement”), dated as of July 26, 2023 (the “Effective Date”), is by and among Robert L. Chioini (“Chioini”), Todd Deutsch (“Deutsch”) and Ted D. Kellner (“Kellner”) (each, a “Party” and, collectively, the “Parties”). Capitalized |
|
| January 3, 2024 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| January 3, 2024 |
AIM / AIM ImmunoTech Inc. / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A 1 d874197dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 200 |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy S |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report November 15, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identi |
|
| November 15, 2023 |
Presentation entitled Q3 2023 Update Conference Call. Exhibit 99.1 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report November 8, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identif |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 8, 2023 |
Exhibit 99.1 |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| October 24, 2023 |
Shaun J. Mathew, P.C. To Call Writer Directly: +1 212 909 3035 Shaun J. Mathew, P.C. To Call Writer Directly: +1 212 909 3035 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 VIA EDGAR AND EMAIL October 24, 2023 Division of Corporation Finance Office of Mergers & Acquisitions United States Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549 Atten |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confiden |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report September 28, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Ident |
|
| September 29, 2023 |
Exhibit 10.1 AMENDED AND RESTATED MATERIAL TRANSFER AND RESEARCH AGREEMENT This Amended and Restated Material Transfer and Research Agreement (“Agreement”) is made as of September 20, 2023 (“Effective Date”), by and between AIM IMMUNOTECH, INC., a Delaware Corporation with a principal place of business located at 2117 SW Highway 484, Ocala, Florida 34473 (“AIM”), and Roswell Park Cancer Institute |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report September 22, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Ident |
|
| September 22, 2023 |
Exhibit 99.1 |
|
| September 22, 2023 |
Exhibit 99.2 AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care OCALA, FL (September 22, 2023) – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the |
|
| August 28, 2023 |
Nomination Notice of Mr. Kellner, dated August 4, 2023 EX-2 Exhibit 2 Ted D. Kellner 790 North Water Street, Suite 2175 Milwaukee, WI 53202 August 4, 2023 VIA OVERNIGHT DELIVERY AND EMAIL AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala, Florida 34473 Attn: Secretary [email protected] Re: Notice of Stockholder Intent to Nominate Individuals for Election as Director at the 2023 Annual Meeting of Stockholders of AIM ImmunoTech Inc. Dear Secretary, Th |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 28, 2023 |
AIM / AIM ImmunoTech Inc / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 2000 Cleveland, Ohio 44114 Attn: |
|
| August 28, 2023 |
Statement of Kellner Group, dated August 28, 2023 EX-1 Exhibit 1 KELLNER GROUP TO PROCEED WITH AIM DIRECTOR NOMINATIONS AND PROXY SOLICITATION Kellner Files Complaint in Delaware Court of Chancery to Enforce Stockholder Rights Stockholders Should Not Be Distracted by Misleading Statements by AIM Kellner Group Nominees Have Skills, Experience and Credibility Necessary for AIM to be Successful Entrenched AIM Board Continues to Waste Corporate Cash and Resources in Attempt to Avoid Accountability to Stockholders Ted D. |
|
| August 23, 2023 |
Exhibit 99.2 AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements Group Seeking to Take Control of 75% of AIM Board Failed to Properly Disclose Myriad Interconnections, Understandings and Arrangements Among Its Members – Violating the Company’s Bylaws and Preventing Shareholders from Being Able to Make |
|
| August 23, 2023 |
Exhibit 99.1 1313 North Market Street P.O. Box 951 Wilmington, DE 19801- 0951 302 984 6000 www.potteranderson.com Michael A. Pittenger [email protected] 302 984-6136 Direct Phone 302 778-6136 Fax August 23, 2023 VIA E-MAIL AND FEDEX John J. Harrington Baker & Hostetler LLP Key Tower, Suite 2000 127 Public Square Cleveland, Ohio 44114-1214 Re: AIM ImmunoTech Inc. Response to Purported N |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 23, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identif |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report August 15, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identifi |
|
| August 15, 2023 |
Presentation entitled Q2 2023 Update. Exhibit 99.1 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorpo |
|
| August 7, 2023 |
AIM / AIM ImmunoTech Inc / Deutsch Todd - SC 13D/A Activist Investment SC 13D/A 1 d522685dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 200 |
|
| July 27, 2023 |
AIM / AIM ImmunoTech Inc / Deutsch Todd - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 AIM IMMUNOTECH INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00901B105 (CUSIP Number) Todd Deutsch Ted D. Kellner c/o Baker & Hostetler LLP 127 Public Square, Suite 2000 Cleveland, Ohio 44114 Attn: John J. Harrington ( |
|
| July 27, 2023 |
Group Agreement among the Reporting Persons and Mr. Chioini EX-2 EXHIBIT 2 Group Agreement THIS AGREEMENT (the “Agreement”), dated as of July 26, 2023 (the “Effective Date”), is by and among Robert L. |
|
| July 27, 2023 |
Joint Filing Agreement of the Reporting Persons EX-1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of the Common Stock of the Company and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report July 10, 2023 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 001-27072 52-0845822 (state or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identifica |
|
| July 10, 2023 |
Presentation entitled Long COVID Q3 2023. Exhibit 99.1 |
|
| July 10, 2023 |
Presentation entitled Oncology Q3 2023. Exhibit 99.2 |
